Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19
We report clinical features, treatments and outcomes in 18 lung transplant recipients with laboratory confirmed SARS-CoV-2 infection. We performed a single center, retrospective case series study of lung transplant recipients, who tested positive for SARS-CoV-2 between 1 February 2020 and 1 March 20...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Transplantology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-3943/2/2/22 |
| _version_ | 1797530118493569024 |
|---|---|
| author | René Hage Carolin Steinack Fiorenza Gautschi Susan Pfister Ilhan Inci Macé M. Schuurmans |
| author_facet | René Hage Carolin Steinack Fiorenza Gautschi Susan Pfister Ilhan Inci Macé M. Schuurmans |
| author_sort | René Hage |
| collection | DOAJ |
| description | We report clinical features, treatments and outcomes in 18 lung transplant recipients with laboratory confirmed SARS-CoV-2 infection. We performed a single center, retrospective case series study of lung transplant recipients, who tested positive for SARS-CoV-2 between 1 February 2020 and 1 March 2021. Clinical, laboratory and radiology findingswere obtained. Treatment regimens and patient outcome data were obtained by reviewing the electronic medical record. Mean age was 49.9 (22–68) years, and twelve (67%) patients were male. The most common symptoms were fever (n = 9, 50%), nausea/vomiting (n = 7, 39%), cough (n = 6, 33%), dyspnea (n = 6, 33%) and fatigue (n = 6, 33%). Headache was reported by five patients (28%). The most notable laboratory findings were elevated levels of C-reactive protein (CRP) and lactate dehydrogenase (LDH). Computed Tomography (CT) of the chest was performed in all hospitalized patients (n = 11, 7%), and showed ground-glass opacities (GGO) in 11 patients (100%), of whom nine (82%) had GGO combined with pulmonary consolidations. Six (33%) patients received remdesivir, five (28%) intravenous dexamethasone either alone or in combination with remdesivir, and 15 (83%) were treated with broad spectrum antibiotics including co-amoxicillin, tazobactam-piperacillin and meropenem. Four (22%) patients were transferred to the intensive care unit, two patients (11%) required invasive mechanical ventilation who could not be successfully extubated and died. Eighty-nine percent of our patients survived COVID-19 and were cured. Two patients with severe COVID-19 did not survive. |
| first_indexed | 2024-03-10T10:24:23Z |
| format | Article |
| id | doaj.art-5e6255de1c8549b48892bce77d407422 |
| institution | Directory Open Access Journal |
| issn | 2673-3943 |
| language | English |
| last_indexed | 2024-03-10T10:24:23Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Transplantology |
| spelling | doaj.art-5e6255de1c8549b48892bce77d4074222023-11-22T00:08:09ZengMDPI AGTransplantology2673-39432021-06-012222924510.3390/transplantology2020022Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19René Hage0Carolin Steinack1Fiorenza Gautschi2Susan Pfister3Ilhan Inci4Macé M. Schuurmans5Division of Pulmonology, University Hospital Zurich, CH 8091 Zurich, SwitzerlandDivision of Pulmonology, University Hospital Zurich, CH 8091 Zurich, SwitzerlandDivision of Pulmonology, University Hospital Zurich, CH 8091 Zurich, SwitzerlandDivision of Internal Medicine, University Hospital Zurich, CH 8091 Zurich, SwitzerlandDepartment of Thoracic Surgery, University Hospital Zurich, CH 8091 Zurich, SwitzerlandDivision of Pulmonology, University Hospital Zurich, CH 8091 Zurich, SwitzerlandWe report clinical features, treatments and outcomes in 18 lung transplant recipients with laboratory confirmed SARS-CoV-2 infection. We performed a single center, retrospective case series study of lung transplant recipients, who tested positive for SARS-CoV-2 between 1 February 2020 and 1 March 2021. Clinical, laboratory and radiology findingswere obtained. Treatment regimens and patient outcome data were obtained by reviewing the electronic medical record. Mean age was 49.9 (22–68) years, and twelve (67%) patients were male. The most common symptoms were fever (n = 9, 50%), nausea/vomiting (n = 7, 39%), cough (n = 6, 33%), dyspnea (n = 6, 33%) and fatigue (n = 6, 33%). Headache was reported by five patients (28%). The most notable laboratory findings were elevated levels of C-reactive protein (CRP) and lactate dehydrogenase (LDH). Computed Tomography (CT) of the chest was performed in all hospitalized patients (n = 11, 7%), and showed ground-glass opacities (GGO) in 11 patients (100%), of whom nine (82%) had GGO combined with pulmonary consolidations. Six (33%) patients received remdesivir, five (28%) intravenous dexamethasone either alone or in combination with remdesivir, and 15 (83%) were treated with broad spectrum antibiotics including co-amoxicillin, tazobactam-piperacillin and meropenem. Four (22%) patients were transferred to the intensive care unit, two patients (11%) required invasive mechanical ventilation who could not be successfully extubated and died. Eighty-nine percent of our patients survived COVID-19 and were cured. Two patients with severe COVID-19 did not survive.https://www.mdpi.com/2673-3943/2/2/22SARS-CoV-2viral infectionhyperinflammationcytokine storm syndromedexamethasoneremdesivir |
| spellingShingle | René Hage Carolin Steinack Fiorenza Gautschi Susan Pfister Ilhan Inci Macé M. Schuurmans Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19 Transplantology SARS-CoV-2 viral infection hyperinflammation cytokine storm syndrome dexamethasone remdesivir |
| title | Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19 |
| title_full | Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19 |
| title_fullStr | Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19 |
| title_full_unstemmed | Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19 |
| title_short | Clinical Characteristics, Treatments and Outcomes of 18 Lung Transplant Recipients with COVID-19 |
| title_sort | clinical characteristics treatments and outcomes of 18 lung transplant recipients with covid 19 |
| topic | SARS-CoV-2 viral infection hyperinflammation cytokine storm syndrome dexamethasone remdesivir |
| url | https://www.mdpi.com/2673-3943/2/2/22 |
| work_keys_str_mv | AT renehage clinicalcharacteristicstreatmentsandoutcomesof18lungtransplantrecipientswithcovid19 AT carolinsteinack clinicalcharacteristicstreatmentsandoutcomesof18lungtransplantrecipientswithcovid19 AT fiorenzagautschi clinicalcharacteristicstreatmentsandoutcomesof18lungtransplantrecipientswithcovid19 AT susanpfister clinicalcharacteristicstreatmentsandoutcomesof18lungtransplantrecipientswithcovid19 AT ilhaninci clinicalcharacteristicstreatmentsandoutcomesof18lungtransplantrecipientswithcovid19 AT macemschuurmans clinicalcharacteristicstreatmentsandoutcomesof18lungtransplantrecipientswithcovid19 |